Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00984399 · OUTCOME

Change in Serum Estradiol Baseline to Week 24

Serum Estradiol Levels In Postmenopausal Women With Breast Cancer Receiving Adjuvant Aromatase Inhibitors and Vaginal Estrogen · Source last updated 2025-12-09

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEAN
Unit
pg/ mL
Interval / dispersion
Full Range
Time frame
24 weeks

What was measured

To describe patterns of estradiol over the twenty-four week study period.

Groups in this outcome

Letrozole

This is a prospective longitudinal pilot study, and the targeted patient population is postmenopausal women with breast cancer being treated with adjuvant aromatase inhibitors who are initiated on vaginal 17β-estradiol to relieve symptoms of atrophic vaginitis.

Anastrozole

This is a prospective longitudinal pilot study, and the targeted patient population is postmenopausal women with breast cancer being treated with adjuvant aromatase inhibitors who are initiated on vaginal 17β-estradiol to relieve symptoms of atrophic vaginitis.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Letrozole12
Anastrozole19

Reported measurements

Baseline Estradiol
Values in pg/ mL · Interval/dispersion: Full Range
GroupValueSpreadLowerUpperComment
Letrozole5.21Not reported0.69.8Not reported
Anastrozole4.46Not reported1.38.8Not reported
Week 24 Estradiol
Values in pg/ mL · Interval/dispersion: Full Range
GroupValueSpreadLowerUpperComment
Letrozole7.55Not reported3.521.6Not reported
Anastrozole9.26Not reported3.323.7Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        0.6
        upper Limit
        9.8
        value
        5.21
      2. group Id
        OG001
        lower Limit
        1.3
        upper Limit
        8.8
        value
        4.46
    title
    Baseline Estradiol
  2. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        3.5
        upper Limit
        21.6
        value
        7.55
      2. group Id
        OG001
        lower Limit
        3.3
        upper Limit
        23.7
        value
        9.26
    title
    Week 24 Estradiol
denoms
  1. counts
    1. group Id
      OG000
      value
      12
    2. group Id
      OG001
      value
      19
    units
    Participants
description
To describe patterns of estradiol over the twenty-four week study period.
dispersion Type
Full Range
groups
  1. description
    This is a prospective longitudinal pilot study, and the targeted patient population is postmenopausal women with breast cancer being treated with adjuvant aromatase inhibitors who are initiated on vaginal 17β-estradiol to relieve symptoms of atrophic vaginitis.
    id
    OG000
    title
    Letrozole
  2. description
    This is a prospective longitudinal pilot study, and the targeted patient population is postmenopausal women with breast cancer being treated with adjuvant aromatase inhibitors who are initiated on vaginal 17β-estradiol to relieve symptoms of atrophic vaginitis.
    id
    OG001
    title
    Anastrozole
param Type
MEAN
reporting Status
POSTED
time Frame
24 weeks
title
Change in Serum Estradiol Baseline to Week 24
type
SECONDARY
unit Of Measure
pg/ mL

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice